Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) specifically designed to target a unique epitope of CD2 subset 1, a cell-surface glycoprotein prevalently expressed on multiple myeloma cells. This targeted approach allows for the direct delivery of cytotoxic agents to the cancer cells, potentially enhancing therapeutic efficacy while minimizing off-target effects. Azintuxizumab vedotin is primarily utilized in research focused on the treatment and understanding of multiple myeloma.
Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) specifically designed to target a unique epitope of CD2 subset 1, a cell-surface glycoprotein prevalently expressed on multiple myeloma cells. This targeted approach allows for the direct delivery of cytotoxic agents to the cancer cells, potentially enhancing therapeutic efficacy while minimizing off-target effects. Azintuxizumab vedotin is primarily utilized in research focused on the treatment and understanding of multiple myeloma.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
